SCHOLAR ROCK HOLDING CORP Share Price Today: Live Updates & Key Insights

SCHOLAR ROCK HOLDING CORP share price today is $45.11, up -1.89%. The stock opened at $45.93 against the previous close of $45.5, with an intraday high of $47.75 and low of $44.11.

SCHOLAR ROCK HOLDING CORP Share Price Chart

SCHOLAR ROCK HOLDING CORP

us-stock
To Invest in {{usstockname}}
us-stock

SCHOLAR ROCK HOLDING CORP Share Price Performance

$45.11 -0.0189(-1.89%) SRRK at 23 Mar 2026 03:20 PM Biotechnology
Lowest Today 44.11
Highest Today 47.75
Today’s Open 45.93
Prev. Close 45.5
52 Week High 49.82
52 Week Low 22.71
Day’s Range: Low 44.11 High 47.75
52-Week Range: Low 22.71 High 49.82
1 day return -
1 Week return +10.9
1 month return -4.99
3 month return -1.19
6 month return +36.78
1 year return +31.97
3 year return +381.25
5 year return -26.87
10 year return -

SCHOLAR ROCK HOLDING CORP Institutional Holdings

FMR Inc 13.39

Siren, L.L.C. 9.42

Samsara BioCapital, LLC 6.00

T. Rowe Price Associates, Inc. 5.99

BlackRock Inc 5.88

Wellington Management Company LLP 5.01

Fidelity Growth Compy Commingled Pl S 4.75

Vanguard Group Inc 4.52

Bellevue Group AG 3.53

Redmile Group, LLC 3.40

Fidelity Growth Company Fund 3.37

State Street Corp 3.28

Orbis Allan Gray Ltd 2.98

BB Biotech AG Ord 2.82

Paradigm Biocapital Advisors LP 2.67

HHG PLC 2.62

Jennison Associates LLC 2.43

Vanguard Total Stock Mkt Idx Inv 2.41

Vanguard Health Care Inv 2.39

Eventide Asset Management, LLC 2.12

State Street® SPDR® S&P® Biotech ETF 1.88

NORGES BANK 1.81

Geode Capital Management, LLC 1.77

Hood River Capital Management LLC 1.76

iShares Russell 2000 ETF 1.74

Driehaus Capital Management LLC 1.70

US Small-Cap Growth II Equity Comp 1.61

T. Rowe Price New Horizons 1.61

Polar Capital Biotech S Inc 1.52

T. Rowe Price Health Sciences 1.44

Fidelity Select Biotechnology 1.44

The Goldman Sachs Group Inc 1.36

Eventide Gilead N 1.27

Fidelity Growth Company K6 1.02

American Funds SMALLCAP World A 0.98

Hood River Small-Cap Growth Instl 0.93

Fidelity Series Growth Company 0.91

Eventide Healthcare & Life Sciences I 0.83

Vanguard Institutional Extnd Mkt Idx Tr 0.80

T. Rowe Price New Horizons Tr-A 0.71

SCHOLAR ROCK HOLDING CORP Market Status

Strong Buy: 6

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

SCHOLAR ROCK HOLDING CORP Fundamentals

Market Cap 5128.38 M

PB Ratio 20.8906

PE Ratio 0.0

Enterprise Value 4869.73 M

Total Assets 404.27 M

Volume 3288473

SCHOLAR ROCK HOLDING CORP Company Financials

Annual Revenue FY23:0 0.0M, FY22:33193000 33.2M, FY21:18816000 18.8M, FY20:15403000 15.4M, FY19:20492000 20.5M

Annual Profit FY23:null 0.0M, FY22:33193000 33.2M, FY21:18816000 18.8M, FY20:15403000 15.4M, FY19:20492000 20.5M

Annual Net worth FY23:-158918000 -158.9M, FY22:-131648000 -131.6M, FY21:-131799000 -131.8M, FY20:-84992000 -85.0M, FY19:-49697000 -49.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-423000 -0.4M, Q2/2025:-417000 -0.4M, Q1/2025:-393000 -0.4M, Q3/2024:null 0.0M, Q2/2024:-498000 -0.5M

Quarterly Net worth Q3/2025:-102220000 -102.2M, Q2/2025:-110031000 -110.0M, Q1/2025:-74723000 -74.7M, Q3/2024:-64479000 -64.5M, Q2/2024:-58508000 -58.5M

About SCHOLAR ROCK HOLDING CORP & investment objective

Company Information Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 289

Industry Biotechnology

CEO Mr. David L. Hallal

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

SCHOLAR ROCK HOLDING CORP FAQs

What is the share price of SCHOLAR ROCK HOLDING CORP today?

The current share price of SCHOLAR ROCK HOLDING CORP is $45.11.

Can I buy SCHOLAR ROCK HOLDING CORP shares in India?

Yes, Indian investors can buy SCHOLAR ROCK HOLDING CORP shares by opening an international trading and demat account with Motilal Oswal.

How to buy SCHOLAR ROCK HOLDING CORP shares in India?

You can easily invest in SCHOLAR ROCK HOLDING CORP shares from India by:

Can I buy fractional shares of SCHOLAR ROCK HOLDING CORP?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of SCHOLAR ROCK HOLDING CORP?

SCHOLAR ROCK HOLDING CORP has a market cap of $5128.38 M.

In which sector does SCHOLAR ROCK HOLDING CORP belong?

SCHOLAR ROCK HOLDING CORP operates in the Biotechnology sector.

What documents are required to invest in SCHOLAR ROCK HOLDING CORP stocks?

To invest, you typically need:

What is the PE and PB ratio of SCHOLAR ROCK HOLDING CORP?

The PE ratio of SCHOLAR ROCK HOLDING CORP is N/A and the PB ratio is 20.89.